[go: up one dir, main page]

BR112021017651A2 - Mutantes sinciciais oncolíticos de herpes simplex como potentes terapêuticas contra o câncer - Google Patents

Mutantes sinciciais oncolíticos de herpes simplex como potentes terapêuticas contra o câncer

Info

Publication number
BR112021017651A2
BR112021017651A2 BR112021017651A BR112021017651A BR112021017651A2 BR 112021017651 A2 BR112021017651 A2 BR 112021017651A2 BR 112021017651 A BR112021017651 A BR 112021017651A BR 112021017651 A BR112021017651 A BR 112021017651A BR 112021017651 A2 BR112021017651 A2 BR 112021017651A2
Authority
BR
Brazil
Prior art keywords
herpes simplex
syncytial
mutants
hsv
cancer therapeutics
Prior art date
Application number
BR112021017651A
Other languages
English (en)
Inventor
K Halley Julia
A Cassady Kevin
Pin-Yi Wang
P Cripe Timothy
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of BR112021017651A2 publication Critical patent/BR112021017651A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C12N15/8695—Herpes simplex virus-based vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00051—Methods of production or purification of viral material
    • C12N2710/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

mutantes sinciciais oncolíticos de herpes simplex como potentes terapêuticas contra o câncer a divulgação fornece um vírus de herpes simplex ("hsv") não natural, composições que compreendem, ou consistem de maneira alternativa essencialmente em, ou consistem ainda em, hsv e métodos de produção de hsv ou infecção de uma célula com hsv. também são fornecidos aqui métodos de tratamento de câncer ou inibição do crescimento ou metástase de células cancerosas num sujeito em necessidade do mesmo.
BR112021017651A 2019-03-14 2020-03-13 Mutantes sinciciais oncolíticos de herpes simplex como potentes terapêuticas contra o câncer BR112021017651A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818577P 2019-03-14 2019-03-14
US201962932725P 2019-11-08 2019-11-08
PCT/US2020/022806 WO2020186238A1 (en) 2019-03-14 2020-03-13 Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics

Publications (1)

Publication Number Publication Date
BR112021017651A2 true BR112021017651A2 (pt) 2021-11-16

Family

ID=72426047

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017651A BR112021017651A2 (pt) 2019-03-14 2020-03-13 Mutantes sinciciais oncolíticos de herpes simplex como potentes terapêuticas contra o câncer

Country Status (11)

Country Link
US (1) US20220154149A1 (pt)
EP (1) EP3937960A4 (pt)
JP (2) JP7671253B2 (pt)
KR (1) KR20210139306A (pt)
CN (1) CN113710259B (pt)
AU (1) AU2020235140A1 (pt)
BR (1) BR112021017651A2 (pt)
CA (1) CA3132867A1 (pt)
IL (1) IL286142A (pt)
SG (1) SG11202109707VA (pt)
WO (1) WO2020186238A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120380154A (zh) * 2022-12-14 2025-07-25 Eg427公司 改良型单纯疱疹病毒1型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131212A0 (en) 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
WO2005005637A2 (en) * 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d
WO2008030560A2 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
JP6726824B2 (ja) * 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
CA2988196C (en) * 2015-05-04 2021-04-27 The Brigham And Women's Hospital, Inc. Oncolytic hsv1 vector and methods of use
US10596234B2 (en) * 2016-10-28 2020-03-24 University Of Southern California Compositions and methods to inhibit viral replication
JP7490365B2 (ja) * 2017-03-09 2024-05-27 シァメン・ユニヴァーシティ 組み換え単純ヘルペスウイルス及びその使用

Also Published As

Publication number Publication date
KR20210139306A (ko) 2021-11-22
JP2022524379A (ja) 2022-05-02
IL286142A (en) 2021-10-31
CA3132867A1 (en) 2020-09-17
EP3937960A4 (en) 2023-03-29
JP7671253B2 (ja) 2025-05-01
CN113710259B (zh) 2024-12-31
EP3937960A1 (en) 2022-01-19
WO2020186238A1 (en) 2020-09-17
US20220154149A1 (en) 2022-05-19
CN113710259A (zh) 2021-11-26
JP2025028186A (ja) 2025-02-28
SG11202109707VA (en) 2021-10-28
AU2020235140A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
MX2021011119A (es) Nueva cepa de paenibacillus, compuestos antifungicos y metodos para su uso.
WO2018129404A8 (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
AR089873A1 (es) Vegetales resistentes al glifosato y metodos asociados
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
MX2011011402A (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MA39867A (fr) Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
MX2021009554A (es) Produccion de virus en cultivos celulares.
MX2007015217A (es) Sistema automatizado de terapia mediante celulas.
NZ595792A (en) Antibodies specific to cadherin-17
BR112021012616A2 (pt) Cepa produtora de ergotioneína e método para triagem da mesma
BR112021019349A2 (pt) Células-tronco preparadas altamente funcionais
WO2022187288A3 (en) Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
BR112018015312A2 (pt) cepa fúngica isolada, cultura biologicamente pura, composição inoculante, kit, uso de uma cepa, e, método para aumentar quantidade/concentração de fosfato solúvel em um meio que contém fosfato insolúvel
WO2021195446A3 (en) Methods and compositions for restoring stmn2 levels
AR056840A1 (es) Celulas hospedantes y metodos de cultivo que implican la sobreexpresion de la man1c1
BR112021025116A2 (pt) Células linfocíticas ativadas e métodos de uso das mesmas para tratar câncer e condições infecciosas
CL2010000774A1 (es) Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso.
BR112021017651A2 (pt) Mutantes sinciciais oncolíticos de herpes simplex como potentes terapêuticas contra o câncer
WO2021015615A8 (en) Low density cell culture
PH12020551328A1 (en) MUTANT á-GLUCOSIDASE
CR7686A (es) Suplemento agricola seguro para el ambiente
ZA202006210B (en) Plant expression enhancer
WO2020067648A3 (ko) 수지상세포를 이용한 면역 소재의 면역증진 효과 평가방법 및 면역 소재 스크리닝 방법